Literature DB >> 27575859

Managing the comorbidity of schizophrenia and ADHD.

Amy Gough1, Jason Morrison1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27575859      PMCID： PMC5008925     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  20 in total

1.  The dopamine dilemma: using stimulants and antipsychotics concurrently.

Authors:  Jason Yanofski
Journal:  Psychiatry (Edgmont)       Date:  2010-06

Review 2.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Authors:  Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W Dittmann; John Graham; Eric Taylor; Joseph Sergeant
Journal:  J Child Psychol Psychiatry       Date:  2013-01-07       Impact factor: 8.982

Review 3.  Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.

Authors:  Molly K Larson; Elaine F Walker; Michael T Compton
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

4.  Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.

Authors:  Blanca Bolea-Alamañac; David J Nutt; Marios Adamou; Phillip Asherson; Stephen Bazire; David Coghill; David Heal; Ulrich Müller; John Nash; Paramala Santosh; Kapil Sayal; Edmund Sonuga-Barke; Susan J Young
Journal:  J Psychopharmacol       Date:  2014-02-12       Impact factor: 4.153

Review 5.  A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities.

Authors:  Jean-Pierre Lindenmayer; Henry Nasrallah; Michael Pucci; Steven James; Leslie Citrome
Journal:  Schizophr Res       Date:  2013-04-22       Impact factor: 4.939

6.  Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later.

Authors:  Rachel G Klein; Salvatore Mannuzza; María A Ramos Olazagasti; Erica Roizen; Jesse A Hutchison; Erin C Lashua; F Xavier Castellanos
Journal:  Arch Gen Psychiatry       Date:  2012-12

7.  Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder.

Authors:  Henrik Larsson; Eleonore Rydén; Marcus Boman; Niklas Långström; Paul Lichtenstein; Mikael Landén
Journal:  Br J Psychiatry       Date:  2013-05-23       Impact factor: 9.319

Review 8.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.

Authors:  Viktória Simon; Pál Czobor; Sára Bálint; Agnes Mészáros; István Bitter
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

9.  Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.

Authors:  Raveen Hanwella; Madhri Senanayake; Varuni de Silva
Journal:  BMC Psychiatry       Date:  2011-11-10       Impact factor: 3.630

Review 10.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.